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In randomized clinical trials, investigators compare the clinical outcomes among treatment 
arms and make claims on the effectiveness of experimental treatments versus the standard ones. 
Recent developments in biotechnology and associated biomarkers have led to advances in 
evaluating heterogeneous patient response and the relationship between treatment responses and 
certain biomarkers. Precision medicine, therefore, is becoming very popular in the healthcare 
industry. It is of great public health significance that proper implementation of precision medicine 
leads to informed and efficient decision making and patient management in clinical practice. 
Traditionally discovery of a predictive marker of treatment benefit is performed via a test of the 
interaction term between treatment and the marker of interest in a regression model that predicts 
the clinical outcome of interest. Recently a new paradigm has been proposed by redefining the 
search for predictive markers, as the search for an optimal individualized treatment rule (ITR) on 
treatment selection. Here we describe this new approach and apply those methods to a breast cancer 
study to identify clinical and genomic markers that are predictive of treatment benefit. The R 
package “personalized” was used in the implementation. Application of some of these methods 
does identify optimal ITRs that lead to improved outcomes based on the empirical estimates. 
However, validation via random splitting of training and testing datasets suggested that the 
findings may be resulted from over-fitting. These ITR-based methods provide a powerful tool for 
us to identify predictive markers for treatment response, but caution should be taken especially 
with high-dimensional marker data. 
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1.1 Individualized Treatment Rules 
In randomized clinical trials, study participants are randomly assigned to a control arm and 
one or several experimental arms. The control arm represents standard regimen or practice and the 
experimental arms represent the new or alternative regimens that are suspected to be superior to 
the control arm in a certain outcome. When the superiority of the experimental regimen is 
demonstrated at the conclusion of a study, the experimental regimen will replace the control 
regimen and become the new standard practice. More studies will be developed to either confirm 
the finding or test whether this newly developed standard can be further improved. This ever-
lasting procedure has been the blue print for drug development and policy improvement in past 
decades. In recent years it has been recognized that patients may respond to the same treatment 
differently, which is caused by the heterogeneity among different individuals. It has becoming an 
emerging issue especially with the availability of large amount of biomarkers and genomic markers 
from recent vast development in biotechnology. For example, breast cancer patients with hormone 
receptor-positive tumors benefit from hormonal treatments such as tamoxifen and anastrozole but 
those with hormone receptor-negative tumors do not.[1,2] Herceptin reduces the risk of recurrence 
by 50% in breast cancer patients with Her2-positive tumors but its benefit in patients with Her2-
negative tumors is minimal if any.[3] Accounting for this heterogeneity represents a significant 
challenge which has motivated the trend toward personalized medicine over recent years.[4, 5] 
Models that use individual characteristics to predict the optimal treatment that achieves the best 
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response are critical for patients and treating physicians to make informed decisions on their 
treatment selection.  
Assuming larger outcomes are preferable, optimal individualized treatment rules (ITRs) 
are the treatment assignment rules that assign the treatment which maximizes the outcome of the 
overall population based on their characteristics. The term ITRs is derived initially from dynamic 
treatment regimes, a concept proposed by Murphy (2003)[6] that focuses more on the change of 
treatment according to participants characteristics along time. A number of studies have been 
conducted on this topic. Qian and Murphy (2011)[7] used 𝑙𝑙1-penalized least squares to estimate the 
optimal ITRs. Zhao et al. (2012) estimated optimal ITR using an outcome-weighted method with 
the hinge loss used. Chen et al. (2017)[8] provided a general framework for subgroup identification 
under different scenarios. Other studies focused on the methodology behind subgroup 
identification. For example, Zhou et al.[9] proposed a different method to address variable selection 
in finding optimal ITRs using residual weighted learning (RWL).  
An R package, “personalized”, has been recently developed to implement some of the 
aforementioned methods for estimating the optimal ITRs under various choices of loss functions 
and providing subgroup identification.[10]  
1.2 A Sub-study of the NSABP Protocol B-41 Trial 
The data considered in this thesis is a subset from the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B-41 clinical trial, a three-armed, randomized, phase III study.[12] 
529 women participants with early stage operable HER2-positive breast cancer were enrolled from 
July 16, 2007 to June 30, 2011. All participants were over 18 years old and had ECOG performance 
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status of 0 or 1 at study entry. Participants were randomly assigned to receive one of three treatment 
regimens with 1:1:1 ratio. Each participant would at first receive four cycles of standard 
doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² intravenously on day 1 every 3 weeks 
followed by four cycles of weekly paclitaxel (80 mg/m²) intravenously on days 1, 8, and 15, every 
4 weeks. Concurrently with weekly paclitaxel, participants would receive either trastuzumab 
weekly, lapatinib daily, or weekly trastuzumab plus lapatinib daily until surgery. All participants 
would receive trastuzumab after surgery until the completion of 52 weeks of HER2-targeted 
therapy. At the end of neoadjuvant treatments of 6 to 7 months, breast surgery (lumpectomy or 
mastectomy) was performed and participants’ pathological response status was ascertained. 
Pathological complete response (pCR) is defined as the absence of any invasive component in the 
resected breast specimen and absence of cancer on H&E evaluation of all resected lymph nodes 
following completion of neoadjuvant therapy (ypT0/Tis ypN0) among participants with HER2-
positive tumors and under neoadjuvant HER2-targeting regimens. The aim of NSABP B-41 trial 
is to compare the two lapatinib-containing treatment arms to the trastuzumab-only arm with pCR 
as the primary endpoint. 
Trastuzumab is the first human epidermal growth factor receptor 2 (HER2) targeting 
monoclonal antibody that was approved by the United States Food and Drug Administration 
(FDA) as a first-line treatment, combined with paclitaxel, for HER2-positive breast cancer. for the 
treatment of HER2-overexpressing metastatic breast cancer (MBC).[13,14] Lapatinib is a small 
molecule inhibitor of epidermal growth factor receptor (EGFR) and HER2. It has been shown that 
trastuzumab can block the signal transaction and thus suppress the overexpressing of HER2.[15] A 
study has shown that lapatinib has synergy effects with trastuzumab.[16] Therefore, it is expected 
that trastuzumab in combination with lapatinib would have more promising outcomes.  
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Among 529 women enrolled in the trial, 519 participants had their pathological response 
determined. Breast pathological complete response was noted in 93 (52·5%, 95% CI 44·9–59·5) 
of 177 participants in the trastuzumab group, 91 (53·2%, 45·4–60·3) of 171 participants in the 
lapatinib group (p=0·9852); and 106 (62·0%, 54·3–68·8) of 171 participants in the combination 
group (p=0·095). Based on these results, the study concluded that substitution of lapatinib for 
trastuzumab did not improve pCR. Although combined HER2-targeted therapy led to higher pCR 
than the regimen with trastuzumab-alone in addition to chemotherapy, the difference was not 
statistically significant. Given that participants achieving pCR have much better prognosis in terms 
of long-term outcomes, discovery of useful prognostic and predictive clinical and genomic markers 
for pCR is imperative for developing rules that optimize treatment benefit for individual 
participants.  
In a correlative study on B-41, the Nanostring PAM50 assay was performed on core biopsy 
samples from 271 study participants prior to neoadjuvant treatments: 94 of them received 
trastuzumab, 95 of them received lapatinib, and the remaining 82 subjects received a combination 
of trastuzumab and lapatinib. The PAM50 assay (using the PAM50-RUO CodeSet) simultaneously 
measures the expression levels of 72 target sequences, including eight endogenous invariant 
mRNA targets, six positive quality control targets, and eight negative quality control targets 
consisting of probes with no sequence homology to human RNA. At the end, expression levels 
from 50 cancer-related genes were recorded and used to determine the intrinsic subtype of the 
tumors among four categories: Luminal A, Luminal B, Her2-enriched and Basal.[17] To better 
understand whether any of the clinical or genomic markers may predict treatment benefit in pCR, 
we considered two sets of analyses: (1) trastuzumab-containing regimens (176 participants in total) 
versus lapatinib only (95 participants), and (2) trastuzumab combined with lapatinib (82 
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participants) versus trastuzumab alone (94 participants). For both comparisons, the recommended 
treatment is compared with the treatment received to determine the optimal treatment, using 
treatment effects. In the following context, we will denote one treatment arm as the “control arm” 
and the other treatment arm as the “treatment arm” for convenience. 
In this thesis, we applied the R package “personalized” to identify an optimal 
individualized treatment rule and determine participant subgroups who would have achieved 
optimal pCR had they followed the estimated optimal treatment rule using data from these 271 
NSABP B-41 trial participants. For each of the two comparisons, we define one treatment regimen 
as the treatment and another as the control for brevity. In the comparison between trastuzumab 
combined with lapatinib and trastuzumab, the former is the treatment; in the comparison between 
trastuzumab containing regimens and lapatinib, trastuzumab containing regimens are the 
treatment. The rule is defined based on a benefit score that is an estimated function of the markers: 
if the benefit score of a study participant is higher than the cut-point, she will be recommended the 
treatment; otherwise, the control will be recommended. Subgroup identification is accomplished 
using three different sets of potential markers: (1) clinical characteristics, including age, race, 
lymph node status, estrogen-receptor status, human epidermal growth factor receptor 2 (HER2) 
status and tumor size, (2) genomic markers, including breast cancer subtype and various genes, 
and (3) both clinical characteristics and genomic markers.  
This thesis is organized as follows. In Section 2, we review and compare different 
methodologies regarding value function approximation, especially the selection of loss functions. 
In Section 3, we apply the methodology discussed in Section 2 on the NSABP B-41 trial data using 
the “personalized” package in R. In Section 4, problems and future studies are discussed. Related 
R code is given in the Appendix A. 
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2.0 Optimal Individualized Treatment Rules 
Randomized clinical trials are designed to compare the efficacy of new treatment regimens 
to that of a standard regimen in terms of average effects across some participant population. When 
there is strong evidence to support the superiority of one of more regimens to the standard one, 
investigators would claim a positive trial and recommend treating similar participants with the 
newly found superior regimen(s) in future practice. This has been the model for drug development 
in many fields of medicine, especially cancer, in past decades. Investigators understand that 
participant response to treatments may not be homogeneous, that is, certain participants would 
benefit from replacing the standard treatment by the new treatment but other participants may not. 
Especially in the treatment of cancer participants, newer treatments such as new antibodies, second 
or third generations of chemotherapies and immunotherapies often lead to unexpected 
complications or deadly adverse events. It becomes imperative to identify markers that can be used 
to determine which participants would benefit from the new treatment and which participants 
would not. The determination of a predictive marker, a patient attribute that can be used to predict 
differential benefit from one treatment over another, is traditionally done via testing the interaction 
between treatment and the marker or participant characteristic under consideration.[18] In the past, 
study design for screening predictive markers of treatment benefit were hampered by two issues: 
(1) a marker study usually requires a quadrupled sample size comparing to a similar superiority 
clinical trial on efficacy; (2) there are very few useful clinical markers. Recent developments in 
microarray and RNA/DNA sequencing technologies provide an unique opportunity for 
investigators to explore predictive utility of the vast amount of genomic signatures. Demands for 
genomic predictive markers of treatment benefit has since stimulated statistical methodologies for 
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providing valid and effective discoveries other than the traditional approach by testing interactions 
in past few years. Recently Qian and Murphy (2011)[7] and Zhao et al. (2012)[19] provided a 
framework for defining ITR and proposed statistical methods to estimate optimal ITRs via 
optimizing a loss function. The methodology of R package “personalized” is mainly based on the 
methods built in this framework by further developments proposed by Xu et al. (2015)[11] and Chen 
et al. (2017)[8]. In the following context, we will use their notations and introduce the framework, 
recently proposed methods and application under the setting of two treatment arms and a binary 
outcome. 
2.1 Individualized Treatment Rule (ITR) 
Assuming that in a randomized clinical trial with two treatments, T, coded as -1 and 1, data 
on the binary outcome 𝑌𝑌 ∈ {0,1} and potential markers 𝑍𝑍 = {𝑍𝑍1,𝑍𝑍2, … ,𝑍𝑍𝑑𝑑} are collected from n 
subjects. Let Λ = {−1,1}, an ITR is a map D from the space of Z to Λ: 𝑇𝑇 = 𝐷𝐷(𝑍𝑍) ∈ Λ. Let 𝑃𝑃𝐷𝐷 
represent the distribution of (𝑇𝑇,𝑌𝑌,𝑍𝑍) under a given ITR D, 𝐸𝐸𝐷𝐷(𝑌𝑌) be the expected value of the 
outcome Y under 𝑃𝑃𝐷𝐷, a larger value of 𝐸𝐸𝐷𝐷(𝑌𝑌) then indicates better outcomes, assuming larger 
outcomes are more desirable. 𝐸𝐸𝐷𝐷(𝑌𝑌) can also be called the value function and be written as 𝑣𝑣(𝐷𝐷). 
An optimal ITR is a treatment assignment rule D that maximizes a value function should D be 
implemented. With observed data {𝑍𝑍,𝑇𝑇,𝑌𝑌}, let 𝜋𝜋 = 𝑃𝑃𝑃𝑃(𝑇𝑇 = 1|𝑍𝑍), a popular value function is: 
𝑣𝑣(𝐷𝐷) = 𝐸𝐸𝐷𝐷(𝑌𝑌) = ∫𝑌𝑌 𝑑𝑑𝑃𝑃𝐷𝐷 = ∫𝑌𝑌 𝑑𝑑𝑃𝑃
𝐷𝐷
𝑑𝑑𝑃𝑃






where, 𝐼𝐼()  is an indicator function. In randomized clinical trials, 𝜋𝜋  is a known constant. In 
observational studies, 𝜋𝜋(𝑍𝑍) is usually estimated from a regression model of T on Z. 
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Subsequently, an optimal ITR, 𝐷𝐷∗, is a rule that maximizes this value function: 
𝐸𝐸𝐷𝐷∗(𝑌𝑌) = max {𝐸𝐸𝐷𝐷(𝑌𝑌),𝑎𝑎𝑙𝑙𝑙𝑙 𝐷𝐷} 
From  
𝐸𝐸(𝑌𝑌|𝑇𝑇 = 1, D) + 𝐸𝐸(𝑌𝑌|𝑇𝑇 = −1, D) − 𝑣𝑣(𝐷𝐷) = 𝐸𝐸 �𝐼𝐼�𝑇𝑇≠𝐷𝐷(𝑍𝑍)�
𝑇𝑇𝑇𝑇+1−𝑇𝑇2
𝑌𝑌�, (2) 
When Y is nonnegative, the optimal ITR 𝐷𝐷∗ should minimize the right hand side of the 
above equation, which can be assessed as a weighted classification error for classifying 𝑇𝑇 using 𝑍𝑍. 








𝑖𝑖=1 𝐼𝐼�𝑇𝑇𝑖𝑖 ≠ 𝐷𝐷(𝑍𝑍𝑖𝑖)�, (3) 








𝑖𝑖=1 𝐼𝐼 �𝑇𝑇𝑖𝑖 ≠ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠�𝑓𝑓(𝑍𝑍𝑖𝑖)��, (4) 
where 𝑓𝑓() is a function from the space of Z to the set of real numbers, R; 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑡𝑡)=1 if 𝑡𝑡 > 0 and 
0 if 𝑡𝑡 < 0, and 𝐷𝐷(Z) is defined as 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠�𝑓𝑓(Z)�. Zhao et al. (2012)[19] linked maximizing the value 
function to minimizing a weighted misclassification error with classifying each subject into -1 or 





the optimal classifier 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠�𝑓𝑓(Z)� will tend to assign this subject to the observed 𝑇𝑇𝑖𝑖. Observations 
associated with small weights will be assigned to the group that is opposite to 𝑇𝑇𝑖𝑖. Minimizing (4) 
is computationally challenging since it is a weighted sum of 0-1 loss functions which are neither 




2.2 Selection of The Loss Function 
 








𝑖𝑖=1 �1 − 𝑇𝑇𝑖𝑖𝑓𝑓(𝑍𝑍𝑖𝑖)�
+
+ 𝜆𝜆𝑛𝑛‖𝑓𝑓‖2, (5) 
where t+ = max (𝑡𝑡, 0) and ‖𝑓𝑓‖ is some norm for function 𝑓𝑓. The penalty term 𝜆𝜆𝑛𝑛‖𝑓𝑓‖2 was added 
for model regularization. One could use a linear combination of Z to represent 𝑓𝑓: 𝑓𝑓(𝑍𝑍) = 𝛽𝛽0 +
𝛽𝛽1𝑍𝑍1 + ⋯+ 𝛽𝛽𝑝𝑝𝑍𝑍𝑝𝑝 or 𝑓𝑓(𝑍𝑍) = ∑ 𝛽𝛽𝑖𝑖𝐾𝐾(𝑍𝑍,𝑍𝑍𝑖𝑖)𝑖𝑖=1,2,…,𝑛𝑛 + 𝛽𝛽0, where 𝐾𝐾(. , . ) is a pre-determined kernel 
function. The estimated ITR will be 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑓𝑓�𝑍𝑍; ?̂?𝛽�) with ?̂?𝛽 obtained from minimizing (5). Zhao et 
al. (2012)[19] named this method as outcome weighted learning (OWL) and showed that the 
empirical risk function (4) under the estimated optimal ITR would converge to the risk function 
(2) under the optimal ITR under some regularity conditions.  
 Chen et al. (2017)[8] provided a general framework for subgroup identification via ITR by 
extending to other types of loss function. Assume that the counterfactual outcomes from a subject 
are 𝑌𝑌(1) and 𝑌𝑌(−1), had the subject taken treatment 𝑇𝑇 = 1 or 𝑇𝑇 = −1, respectively. In practice, 
only one of the two counterfactual outcomes can be observed from a participant, 𝐼𝐼(𝑇𝑇 = 1)𝑌𝑌(1) and 
𝐼𝐼(𝑇𝑇 = −1)𝑌𝑌(−1) can be used to denote the participant’s outcome result, where 𝐼𝐼(∙) is the indicator 
function for each value of Y. The propensity score Pr(𝑇𝑇 = 1|𝑍𝑍) = 𝜋𝜋(𝑍𝑍) is always known in 
randomized trials, and can be estimated in observational studies. Assuming 𝑓𝑓(𝑍𝑍) is a function of 
baseline covariates that can be used to predict treatment assignment via 𝐷𝐷(𝑍𝑍) = 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠�𝑓𝑓(Z)�, then 




 is increasing in 𝑣𝑣 for any given 𝑦𝑦, (2) 𝑈𝑈(𝑦𝑦) ≡ 𝑀𝑀𝑣𝑣(𝑦𝑦, 0) is monotone in 𝑦𝑦, Chen et al. 
(2017)[8] considered minimizing the risk function 𝑙𝑙𝑊𝑊(𝑓𝑓) = 𝐸𝐸�𝑙𝑙𝑊𝑊(𝑓𝑓,𝑍𝑍)� where: 
𝑙𝑙𝑊𝑊(𝑓𝑓, 𝑧𝑧) = 𝐸𝐸 �
𝑀𝑀{𝑌𝑌,𝑇𝑇𝑓𝑓(𝑍𝑍)}
𝑇𝑇𝜋𝜋(𝑍𝑍) + (1 − T)/2
|𝑍𝑍 = 𝑧𝑧� 
= 𝐸𝐸[𝑀𝑀{𝑌𝑌,𝑓𝑓(𝑍𝑍)}|𝑇𝑇 = 1,𝑍𝑍 = 𝑧𝑧] + 𝐸𝐸[𝑀𝑀{𝑌𝑌,−𝑓𝑓(𝑍𝑍)}|𝑇𝑇 = −1,𝑍𝑍 = 𝑧𝑧]. 
Chen et al. (2017)[8] proposed to define the optimal ITR as {𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑓𝑓𝑊𝑊0(𝑍𝑍)} that minimizes the above 
risk function, where 𝑓𝑓𝑊𝑊0(𝑍𝑍) = 𝑎𝑎𝑃𝑃𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑓𝑓𝑙𝑙𝑊𝑊(𝑓𝑓).  
For the OWL method by Zhao et al. (2012)[19], the loss function M(y,v)=y max{1-v,0}. A couple 
of other loss functions were suggested by Chen et al. (2017)[8], for example, M(y,v)=(y-v)2 for 
continuous outcome y and M(y,v)=-[yv-log{1+exp(-v)}] for binary outcome y.  
Using an approximation similar to the OWL method with 𝑓𝑓𝑊𝑊 = ∑ 𝛽𝛽𝑘𝑘𝐵𝐵𝑘𝑘(𝑍𝑍)𝐾𝐾𝑘𝑘=1 , where 
𝐵𝐵𝑘𝑘(𝑍𝑍),𝑘𝑘 = 1, … ,𝐾𝐾  are some basis functions, one can estimate 𝛽𝛽  by minimizing the empirical 
version of the loss function. Then use 𝑓𝑓𝑊𝑊� = ∑ 𝛽𝛽𝑘𝑘�𝐵𝐵𝑘𝑘(𝑍𝑍)𝐾𝐾𝑘𝑘=1  as the benefit score to define the 
optimal ITR as sign(𝑓𝑓𝑊𝑊� ). In practice when the dimension of Z is large, Chen et al. (2017)[8] 
recommended applying regularization on the variable selection via adding a penalty term.  
In randomized clinical trials, where the treatment assignment is independent from 𝑍𝑍, one 
could readily estimate the improvement conditional on treatment by following quantities: 
𝐸𝐸(𝑌𝑌|𝐷𝐷∗(𝑍𝑍) = 1, T = 1) − 𝐸𝐸(𝑌𝑌|𝐷𝐷∗(𝑍𝑍) = 1, T = −1), 
and 
𝐸𝐸(𝑌𝑌|𝐷𝐷∗(𝑍𝑍) = −1, T = −1) − 𝐸𝐸(𝑌𝑌|𝐷𝐷∗(𝑍𝑍) = −1, T = 1), 
where 𝐷𝐷∗() is the estimated optimal ITR.  
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2.3 Validation 
In practice, investigators will try various basis functions and assess the performance of the 
estimated optimal ITR by comparing the empirical risk function under various settings. As with 
any complex modeling of high dimensional data, over-fitting of the data may lead to overly 
enthusiastic results. As one approach to reduce the potential for overfitting, Huling and Yu 
(2018)[10] recommended an internal validation procedure by randomly splitting the observed data 
into a training set and a testing set. In each split, the optimal ITR developed from the training set 
is applied to the testing test and assess the improved performance in outcome had the estimated 
optimal ITR been followed. For example, for a randomized clinical trial, one may identify 
subgroups in the testing data 𝐸𝐸𝑗𝑗,𝑘𝑘 = {𝑠𝑠:𝑇𝑇𝑖𝑖 = 𝑗𝑗,𝐷𝐷(𝑧𝑧𝑖𝑖) = 𝑘𝑘}, 𝑗𝑗,𝑘𝑘 = −1,1. Then assess the stability of 
results by comparing the empirical means of the response variable between 𝐸𝐸−1,−1 and 𝐸𝐸1,−1, and 
between 𝐸𝐸−1,1 and 𝐸𝐸1,1. If the markers under consideration are informative in predicting treatment 
benefit, one would observe consistent improvement in average response between patients who 
were assigned to the estimated optimal ITR and those who were not across these numerous random 
splittings. Failure in producing a consistent pattern of improvement may indicate that there is no 
strong evidence from the data to support the predictive utility of those markers. However, the lack 
of evidence may due to two possibilities: (1) the markers are not informative and the proposed 
algorithm for obtaining an optimal ITR is over-fitting the data, (2) the decrease in sample size in 
the random splitting practice leads to reduced power for detecting an optimal ITR based on those 
markers.  
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2.4 The “personalized” Package in R 
The “personalized” package is built by Huling and Yu (2018) under the framework 
proposed by Chen et. Al (2017).[8] This package provides a quick and convenient way for subgroup 
identification. For a given data with covariate Z, outcome of interest Y and treatment 𝑇𝑇 = 1 or 
𝑇𝑇 = −1, users are able to use the covariates Z to predict the optimal treatment between 𝑇𝑇 = 1 and 
𝑇𝑇 = −1 that can maximize the expected outcome of interest under the given treatment assignment 
rule. A propensity score function, which is a function that uses subject covariates to predict the 
probability of treatment T = 1, needs to be specified before subgroup identification. Then, the main 
build-in function of this package, fit.subgroup(), can be used to identify treatment subgroups. 
Within this function, loss function for benefit score calculation and the cut-off point for treatment 
assignment can be selected. Many loss functions that satisfies the assumptions in Section 2.2 are 
available: square loss 𝑀𝑀(𝑦𝑦, 𝑣𝑣) = (𝑦𝑦 = 𝑣𝑣)2, the logistic loss 𝑀𝑀(𝑦𝑦, 𝑣𝑣) = 𝑦𝑦 ∗ 𝑙𝑙𝑙𝑙𝑠𝑠(1 + 𝑒𝑒𝑒𝑒𝑒𝑒{−𝑣𝑣}), 
the hinge loss 𝑀𝑀(𝑦𝑦, 𝑣𝑣) = 𝑦𝑦 ∗ max (0, 1 − 𝑣𝑣) etc. Loss function can be specified under the option 
loss within fit.subgroup() function. Under each loss function, the option cutpoint allows users to 
define the cut-off value for treatment recommendation. The cutpoint can be a constant or a quantile 
of benefit scores. The average outcomes within each subgroup by treatment they received are then 
reported in the output, together with the improvement of outcome following the subgroup 
separation and the range of benefit scores.  
These results can be biased estimates because the implemented ITR is estimated from the 
same dataset with high-dimensional marker data, and the imbedded variable selection and model 
regularization would lead to overfitting. Validation is therefore necessary. Using the build-in 
function validate.subgroup(), unbiased results can be obtained by bootstrap bias correction or 
repeated training/testing splitting by choosing between method = "boot" or method = 
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"training_test_replication". For boostrap bias correction, a statistic is first estimated by the 
training data, then the bias with regard to that statistic is estimated by bootstrap samples extracted 
with replacement using whole data. Then a bias-corrected statistic can be obtained by these two 
values. For repeated training/testing splitting method, data is randomly partitioned into training 
and testing sets at a ratio that can be defined arbitrarily by users, the average outcome values for 
the training set, thus the predicted average outcomes given the same covariates under different 
treatment, are then estimated by the empirical average of outcomes in the testing set. This method 
allows us to obtain unbiased assessment on the implementation of the estimated optimal ITR in 
the study population. Many replications are performed for both methods. 
Plots of average outcomes within each subgroup by treatment status are available after 
fit.subgroup() or validate.subgroup(). Available options are boxplot, density plot, conditional plot 
and interaction plot specified by “type = ” option. Boxplots reflect the range and quantiles of 
average outcomes; density plots describe the distribution of the average outcomes; conditional 
plots show the relationship between benefit scores and the smoothed mean outcomes conditional 
on treatment received; interaction plots display the interaction of average outcomes for different 
subgroups and treatment status. Figure 1 to Figure 4 show an example of the four kind of graphs 
from a simulation study with a binary outcome.  
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Figure 1 Example Boxplot 
Figure 2 Example Density Plot 
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Figure 3 Example Conditional Plot 
Figure 4 Example Interaction Plot 
One convenient way to check the improvement from following an ITR would be look at 
the conditional plot and interaction plot. As Figure 3 shows, outcome for the control group (red 
line) decreases as benefit score increases; outcome for the treatment group (blue line) increases as 
benefit score increases. A non-parallel pattern of conditional plot like this indicates that following 
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the ITR improves the overall outcome. In Figure 4, a crossed graph means that patients have higher 
outcome, hence better response, when they received recommended treatment, suggesting benefit 
from ITRs. For the sake of brevity, this thesis will mainly discuss interaction plots as an indicator 
for improvement from ITRs. 
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3.0 Application to The NSABP B-41 Study 
3.1 Analytical Methods 
The NSABP B-41 trial data was collected from 271 adult participants with operable HER2-
positive breast cancer. During their neoadjuvant chemotherapy, 82 of these participants received 
trastuzumab, 95 participants received a combination of trastuzumab and lapatinib, and the rest 94 
participants received lapatinib only. Mastectomy or lumpectomy surgery was then performed after 
the treatment. Collected baseline covariates includes clinical markers such as age, race, and 
genomic markers, such as breast cancer subtype and cancer related gene expression. The outcome 
of interest, also the primary endpoint of NSABP B-41 trial, is pCR that coded as 1 or 0, with 1 
represents complete response, 0 otherwise. Participants with a benefit score higher than the 
cutpoint would be assigned to the treatment, otherwise, the control would be recommended. Under 
each subgroup of treatment recommendation, the average outcome of participants who received 
the recommendation and the average outcome of participants who did not received the 
recommendation are compared, then treatment effects conditional on subgroups, 𝐸𝐸[𝑌𝑌|𝑇𝑇 =
𝐶𝐶𝑡𝑡𝑃𝑃𝑙𝑙,𝑇𝑇 = 𝑅𝑅𝑒𝑒𝑅𝑅𝑙𝑙𝑎𝑎] − 𝐸𝐸[𝑌𝑌|𝑇𝑇 ≠ 𝐶𝐶𝑡𝑡𝑃𝑃𝑙𝑙,𝑇𝑇 = 𝑅𝑅𝑒𝑒𝑅𝑅𝑙𝑙𝑎𝑎]  for the control, and 𝐸𝐸[𝑌𝑌|𝑇𝑇 = 𝑇𝑇𝑃𝑃𝑡𝑡,𝑇𝑇 =
𝑅𝑅𝑒𝑒𝑅𝑅𝑙𝑙𝑎𝑎] − 𝐸𝐸[𝑌𝑌|𝑇𝑇 ≠ 𝑇𝑇𝑃𝑃𝑡𝑡,𝑇𝑇 = 𝑅𝑅𝑒𝑒𝑅𝑅𝑙𝑙𝑎𝑎] for the treatment, are computed.  
The purpose of this thesis is to examine if there is the application of ITRs application on 
the NSABP B-41 trial data would improve the outcome. As previous studies have proven, 
trastuzumab has significantly better efficacy than lapatinib on treating HER2 positive breast 
cancer.[12,20] Our focus is thus the comparison of trastuzumab plus lapatinib (T + L) versus 
trastuzumab. We also compared treatment effects between trastuzumab containing treatment, thus 
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trastuzumab alone or trastuzumab plus lapatinib (trastuzumab-containing regimens), and lapatinib 
in order to detect participants with gene types that are more sensitive to lapatinib.  
Three types of models are constructed using the variables in the data, clinical marker 
models, genomic marker models and overall models. The clinical marker models include age, race, 
lymph node status, HER2 gene status, estrogen-receptor status and tumor size. Due to the fact that 
fit.subgroup cannot handle missing data, subjects with missing values have to be removed from 
the analysis (29 out of 176, 16.5%, subjects removed for T + L VS Trastuzumab and 53 out of 
271, 19.6%, subjects for trastuzumab containing regimens VS lapatinib). To avoid overfitting in 
later validation process, we choose to remove variables with more than 30 missing values. Here, 
tumor grade is removed from clinical marker models because it has too many missing values. The 
gene models are constructed by breast cancer subtype and gene expression of 58 genes. The overall 
models use all covariates in clinical markers and genomic markers. Generalized additive model 
(GAM) only applies to continuous variables, but categorical variables are included in each of these 
model. Therefore, we did not use GAM as the loss function. The hinge loss is used instead. For 
each of the three kinds, four scenarios are applied: (1) subgroup identification using the logistic 
loss; the median value of benefit scores is set as the cutoff point for treatment recommendation. 
(2) subgroup identification using the logistic loss; 0 is set as the cutoff point for treatment 
recommendation. (3) subgroup identification using the hinge loss and Gaussian, thus Radial Basis 
Function (RBF) kernel; the median value of benefit scores is set as the cutoff point for treatment 
recommendation. (4) subgroup identification using the hinge loss and Gaussian (RBF) kernel; 0 is 
set as the cutoff point for treatment recommendation. The models under the logistic loss uses the 
loss function 𝑀𝑀(𝑦𝑦, 𝑣𝑣) = 𝑦𝑦 ∗ 𝑙𝑙𝑙𝑙𝑠𝑠(1 + 𝑒𝑒𝑒𝑒𝑒𝑒{−𝑣𝑣}), which is specified by setting the option loss to 
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"logistic_loss_lasso", while the hinge loss uses the loss function 𝑀𝑀(𝑦𝑦, 𝑣𝑣) = 𝑦𝑦 ∗ max (0, 1 − 𝑣𝑣) 
specified by "owl_hinge_loss".  
Treatment effects of the two recommendation groups might balance out and cause a 
seemingly overall beneficial treatment effect value when treatment effects of the two subgroups 
have similar absolute values but of different signs. To better examine the gain from individualized 
treatment assignment, treatment effects conditional on subgroups are reported instead. Positive 
treatment effects for both groups means the following the recommendation would improve the 
outcome.  
To evaluate overoptimism of the estimated treatment rule and to obtain unbiased results, 
we perform validation by splitting the data into the training sets and the testing sets repeatedly. 
Here, we use 25% of the data as the training sets, and the rest 75% as the testing sets. The data is 
first randomly partitioned into these two sets, then subgroup treatment effects for the training sets 
are estimated by empirical average values of treatment effects in the testing sets. As the number 
of replications increases, the average results for all replications would approach the real values, 
and we can obtain unbiased estimates of the average outcomes for the training set. The number of 
replications is set to 100 in this study. 
3.2 Results 
3.2.1  T + L Versus Trastuzumab 
In this section, we compare treatment effects between T + L and trastuzumab. Participants 
in the treatment group are those who received trastuzumab plus lapatinib during neoadjuvant 
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therapy (82 subjects), and participants in the control group received only lapatinib during 
neoadjuvant therapy (94 subjects). After deleting subjects with missing values, there are 72 
participants left in T + L group, and 75 participants in Trastuzumab group. 
We first use clinical markers to find the optimal individualized treatment. For the sake of 
simplicity, we use the numbers of scenarios stated in Section 3.1 to describe each setting. We first 
assess the results of optimal ITRs using the data itself without validation. Under each scenario, 
participants who received the recommended treatment have larger outcomes, and positive 
treatment effects for each subgroup are obtain, meaning the individualized treatment assignment 
improve the outcomes. For clinical marker models, the results of scenario (1) and (2) are shown in 
Table 1. Cut-points are specified in the parentheses after row names. The number in each cell is 
the average outcome of participants under that situation, and n marks the number of participants 
in each category. When we set the median value of benefit scores as the cutpoint, 78 participants 
are assigned to the control and 69 participants are assigned to the treatment. When 0 is used as the 
cut-point, 70 participants are assigned to the control and 77 participants are assigned to the 
treatment In both subgroups, treatment effects are positive. Less participants are assigned to the 
treatment in scenario (1). Higher average outcomes and treatment effect for each treatment group 
are achieved in scenario (1). Figure 5 to 8 show boxplot, density plot, interaction plot and 
conditional plot for scenario (1), respectively. It is clearer in the graphs that participants always 
have higher outcomes when they received the recommendation than when they received the other 
treatment. From Figure 7, the interaction plot, we can measure the gain of ITRs by the difference 
of average outcomes for each treatment. Figure 9 shows the comparison between scenario (1) and 
scenario (2), with the graph to the left representing scenario (1) and the graph to the right 
representing scenario (2). It can be observed that the blue line representing received treatment to 
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the right has a smaller slope, meaning that the improve of outcomes is smaller in scenario (2) when 
participants follow the treatment recommendation. This corresponds to what we observes in Table 
1. In following analysis, we will only report the comparison of interaction plots of different 
scenarios since they are more straightforward.  
 









Received Control  0.65 (n = 40) 0.4 (n = 35) 
Received Treatment 0.53 (n = 38) 0.62 (n = 34) 
Improvement  0.12 (n = 78) 0.22 (n = 69) 
 
0 
Received Control  0.69 (n = 36) 0.38 (n = 39) 
Received Treatment  0.56 (n = 34) 0.58 (n = 38) 
Improvement  0.14 (n = 70) 0.19 (n = 77) 
 
 




Figure 6 T + L (Treatment) VS. Trastuzumab (Control), Clinical Markers, Scenario(1), Desnsity Plot 
 
 
Figure 7 T + L (Treatment) VS. Trastuzumab (Control), Clinical Markers, Scenario(1), Interaction Plot 
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Figure 8 T + L (Treatment) VS. Trastuzumab (Control), Clinical Markers, Scenario(1), Conditional Plot 
Figure 9 T + L (Treatment) VS. Trastuzumab (Control), Clinical Markers, Scenario (1) &(2) 
Next, we examine the results using the hinge loss and Gaussian kernel. Table 2 shows the 
results of scenario (3) and scenario (4). The change of cutpoint does not significantly influence 
resulted treatment effects. More participants are assigned to the treatment group when 0 is set as 
the cut-point. The comparison plot of different cutpoints (Figure 10) shows that using 0 as the cut-
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point (the graph to the right) leads to better improvement of the outcome. Figure 11 and Figure 12 
show the comparisons between different loss functions when the cutpoint remains the same. The 
graphs in Figure 11 is resulted from the clinical marker models using the logistic loss (left) and 
the hinge loss (right). The median value of benefit scores is set as the cutpoint for both models. 
The graphs in Figure 12 shows the comparison between the logistic loss (left) and the hinge loss 
(right) for clinical marker models using 0 as the cutpoint. The hinge loss separate the participants 
in a more strict way, since the average outcomes of participants who received the same treatment 
in both subgroups differs more distinctively in scenario (3) and (4). 
 









Received Control  0.67 (n = 49) 0.27 (n = 26) 
Received Treatment  0.32 (n = 25) 0.70 (n = 47) 
Improvement  0.35 (n = 74) 0.43 (n = 73) 
 
0 
Received Control  0.71 (n = 49) 0.19 (n = 26) 
Received Treatment  0.16 (n = 19) 0.72 (n = 53) 





Figure 10 T + L (Treatment) VS. Trastuzumab (Control), Clinical Markers, Scenario (3) &(4) 
 
 
Figure 11 T + L (Treatment) VS. Trastuzumab (Control), Clinical Markers, Scenario (1) &(3) 
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Figure 12 T + L (Treatment) VS. Trastuzumab (Control), Clinical Markers, Scenario (2) &(4) 
The individualized treatment rule is then evaluated using genomic markers. The estimated 
treatment effects are shown in Table 3. Although both subgroups have positive treatment effects, 
the values under scenario (1) are smaller than values under scenario (2). Besides, the number of 
participants in the control recommended group varies greatly. Most participants (137/176) are 
assigned to the treatment under scenario (2), and the distribution of participants is less balanced 
within each subgroup. As shown in Figure 13, the estimated average outcomes of both subgroups 
varies more dramatically for participants who received the control, but they remain relatively 
stable for participants who received the treatment.  







Received Control 0.60 (n = 47) 0.47 (n = 47) 
Received Treatment 0.56 (n = 41) 0.56 (n = 41) 
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Improvement 0.04 (n = 88)         0.09 (n = 88) 
0 
Received Control 0.84 (n = 25) 0.42 (n = 69) 
Received Treatment 0.57 (n = 14) 0.56 (n = 68) 
Improvement 0.27 (n = 39) 0.14 (n = 137) 
Figure 13 T + L (Treatment) VS. Trastuzumab (Control), Genomic Markers, Scenario (1) & (2) 
We then change the loss function to the hinge loss, using Gaussian kernel. Similarly, 
participants are evenly assigned to both treatments under scenario (3) when the median benefit 
score is chosen as the cutpoint, but more participants are recommended the treatment when 0 is 
the cutpoint. The comparison plot of interactions (Figure 14) shows that under scenario (4), the 
average outcome of participants who received the treatment but assigned to the control and that of 
participants who received the treatment and assigned to the treatment are closer to each other 
(right), compared with scenario (3) (left). For the control recommended subgroup, this difference 
is smaller. When the four scenarios are compared together, the hinge loss seems to separate the 
Table 3 Continued
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data better, especially for participants who received the treatment. As shown in the comparison 
plot between scenario (1) to the left and scenario (3) to the right (Figure 15), and the comparison 
plot between scenario (2) to the left and scenario (4) to the right (Figure 16), the blue line that 
representing participants who received T + L have steeper slopes in graphs to the right. This means 
that the average outcome of these participants in each subgroups differs more significantly than 
that of participants who received trastuzumab, the control. 







Received Control 0.68 (n = 65) 0.21 (n = 29) 
Received Treatment 0.26 (n = 23) 0.68 (n = 59) 
Improvement 0.42 (n = 88) 0.47 (n = 88) 
0 
Received Control 0.75 (n = 51) 0.28 (n = 43) 
Received Treatment 0.41 (n = 22) 0.62 (n = 60) 
Improvement 0.34 (n = 73) 0.34 (n = 103) 
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Figure 14 T + L (Treatment) VS. Trastuzumab (Control), Genomic Markers, Scenario (3) & (4) 
Figure 15 T + L (Treatment) VS. Trastuzumab (Control), Genomic Markers, Scenario (1) & (3) 
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Figure 16 T + L (Treatment) VS. Trastuzumab (Control), Genomic Markers, Scenario (2) & (4) 
All covariates, both clinical markers and genomic markers, are then combined together to 
evaluate the gain from ITR under the same scenarios. For scenario (1) and (2), the choice of 
cutpoint yields great influence to treatment effects. 74 participants are assigned to the control under 
scenario (1), but only 5 participants are in the same subgroup under scenario (2). Almost all 
participants are assigned to the treatment under scenario (2) (See Table 5). Participants are 
unevenly distributed for the control recommended group under scenario (2), which leads to a high 
treatment effect 0.75 since the only participant in the category “received the treatment but 
recommended the control” has an outcome of 0. In Figure 17, the graph to the right represents 
scenario (2). The steep slope of the blue line representing participants who received T + L is 
resulted from the above mentioned uneven distribution. The red lines in both graphs represent 
participants who received the control, and they are approximately parallel. 
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Received Control 0.64 (n = 42) 0.39 (n = 33) 
Received Treatment 0.56 (n = 32) 0.58 (n = 40) 
Improvement 0.08 (n = 74) 0.18 (n = 73) 
0 
Received Control 0.75 (n = 4) 0.52 (n = 71) 
Received Treatment 0 (n = 1) 0.58 (n = 71) 
Improvement 0.75 (n = 5) 0.06 (n = 142) 
Figure 17 T+L (Treatment) VS Trastuzumab (Control), All Covariates, Scenario (1) & (2) 
We then move on to scenario (3) and (4), where the loss function is the hinge loss using 
Gaussian kernel. Overall, no significant change is observed as the cutpoint varies. The median 
benefit score is more restricted than 0 as the cutpoint, since more people under scenario (4) are 
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assigned to the treatment. In Figure 18, the graph to the left shows the interaction of average 
outcomes under scenario (3), and the graph to the right shows the interaction of average outcomes 
under scenario (4). The average outcome of participants who received the control in both 
subgroups remains relatively stable when the cutpoint varies, but that of participants who received 
the treatment is a little higher under scenario (3), meaning a slightly better separation of T + L 
sensitive participants. Similarly, Figure 19 and Figure 20 show the comparison of treatment effects 
of different loss function using same cutpoints. Compared to scenario (1) in Figure 19 (left), 
scenario (3) to the right of Figure 19 better improves the outcome, since the average outcomes of 
two subgroups differ greatly in the plot to the right. When 0 is set as the cutpoint, scenario (2) 
achieves better improvement for the treatment (Figure 20to the left), but scenario (3) achieves 
better improvement for the control (Figure 20 to the right). 







Received Control 0.70 (n = 54) 0.095(n = 21) 
Received Treatment 0.25 (n = 20) 0.69 (n = 52) 
Improvement 0.45 (n = 74) 0.60 (n = 73) 
0 
Received Control 0.80 (n = 41) 0.21 (n = 34) 
Received Treatment 0.25 (n = 12) 0.63 (n = 60) 
Improvement 0.55 (n = 53) 0.43 (n = 94) 
33 
Figure 18 T + L (Treatment) VS. Trastuzumab (Control), All Covariates, Scenario (3) & (4) 
Figure 19 T + L (Treatment) VS. Trastuzumab (Control), All Covariates, Scenario (1) & (3) 
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Figure 20 T + L (Treatment) VS. Trastuzumab (Control), All Covariates, Scenario (2) & (4) 
Overall, the subgroup identification results under all scenarios look promising that the 
application of ITRs to the NSABP B-41 trail data can improve the outcome both for those who 
received trastuzumab combined with lapatinib and for those who received trastuzumab alone. 
However, as previous stated, above results can be biased estimates of treatment effects, since the 
comparison of treatment effects of same participants under different treatments is not conducted. 
In order to obtain unbiased results, we then conduct validations. The results displayed below are 
average values of the 100 replications, with SE indicating the standard error of that value among 
all replications. This also leads to non-integer values of sample sizes (n) in each category. 
For clinical marker models using the logistic loss, the results of subgroup separation change 
significantly after validation. Under both scenarios, treatment effects of control recommendation 
groups become negative, meaning participants have better outcomes when not following the 
recommendation. Although treatment effects remain the same for treatment recommendation 
groups, their values are small (Table 7). Besides, in each subgroup, participants who received the 
treatment always have higher outcomes. This can also be reflected in Figure 21, with the plot to 
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the left representing scenario (1) and the plot to the right representing scenario (2). For all 
participants, those who are recommended the control have higher outcomes on average under both 
scenarios. This seems contrary to what we observed that patients always have higher outcome on 
average when receiving the treatment. However, if we further examine the scale of the interaction 
plot, the difference of average outcomes between two subgroups are pretty small, less or around 
0.1. This difference is likely to be caused by some noise and therefore can be ignored. 
Table 7 T + L (Treatment) VS. Trastuzumab (Control), Validated Clinical Markers, the Logistic Loss 
Cut-off Recommended Control Recommended Treatment 
Median 
Received Control 0.57 (SE = 0.1395, n = 15.07) 0.47 (SE = 0.1814, n = 3.74) 
Received Treatment 0.59 (SE = 0.1039, n = 14.44) 0.54 (SE = 0.1509, n = 3.75) 
Improvement -0.02 (SE = 0.1353, n = 29.51) 0.07 (SE = 0.2889, n = 7.49) 
0 
Received Control 0.56 (SE = 0.1542, n = 6.66) 0.44 (SE = 0.1311, n = 12.56) 
Received Treatment 0.58 (SE = 0.2023, n = 6.76) 0.56 (SE = 0.1562, n = 11.02) 
Improvement -0.02 (SE = 0.1908, n = 13.42) 0.12 (SE = 0.1712, n = 23.58) 
Figure 21 T + L (Treatment) VS. Trastuzumab (Control), Validated Clinical Markers, Scenario (1) & (2) 
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We then examine the validated results for clinical marker models using the hinge loss. 
Under both scenario (3) and (4), we correctly assign participants into two subgroups in a way that 
participants in both subgroups have positive treatment effects, thus higher outcome values when 
follow the recommendations (Table 8). Appear in the interaction plots of average outcomes (Figure 
22), two lines representing different treatment status crossed in both plot, meaning that for some 
patients, receiving the control would lead to better response than the treatment. However, this 
improvement is very small. Under both cutpoints, the improvement is less than 0.05, which is 
almost negligible. 
Table 8 T + L (Treatment) VS. Trastuzumab (Control), Validated Clinical Markers, the Hinge Loss 
Cut-off Recommended Control Recommended Treatment 
Median 
Received Control 0.60 (SE = 0.1592, n = 9.42) 0.45 (SE = 0.1288, n = 9.51) 
Received Treatment 0.56 (SE = 0.1389, n = 9.58) 0.65 (SE = 0.1073, n = 8.49) 
Improvement 0.04 (SE = 0.2078, n = 19) 0.20 (SE = 0.1682, n = 18) 
0 
Received Control 0.59 (SE = 0.1659, n = 5.83) 0.47 (SE = 0.1271, n = 13.15) 
Received Treatment 0.56 (SE = 0.1441, n = 6.76) 0.69 (SE = 0.1307, n = 11.26) 
Improvement 0.02 (SE = 0.2419, n = 12.59) 0.22 (SE = 0.2015, n = 24.41) 
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Figure 22 T + L (Treatment) VS. Trastuzumab (Control), Validated Clinical Markers, Scenario (3) & (4) 
Genomic marker models using the logistic loss do not achieve meaningful separation after 
validation. Under both scenario (1) and (2), participants always have better outcomes when they 
receive the treatment, trastuzumab plus lapatinib, regardless of the recommended treatment (Table 
9). As the cutpoint varies, the gain of ITR for does not vary much for the control recommendation. 
Under scenario (2), the absolute value of treatment effect decreases for the treatment 
recommendation, but it increases for the control group. Also, the number of participants that is 
assigned to the treatment increases. For all subgroups under both scenarios, participants who are 
recommended the control have higher outcomes on average. This is especially apparent under 
scenario (1), within participants who received the control, trastuzumab only (Figure 23). 
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Table 9 T + L VS Trastuzumab, Validated Gene Models, the Logistic Loss 
Cut-off Recommended Control Recommended Treatment 
Median 
Received Control 0.58 (SE = 0.1217, n = 14.36) 0.43 (SE = 0.1592, n = 8.84) 
Received Treatment 0.60 (SE = 0.164, n = 11.6) 0.56 (SE = 0.1099, n = 9.2) 
Improvement -0.02 (SE = 0.1702, n = 25.96) 0.13 (SE = 0.1602, n = 18.04) 
0 
Received Control 0.57 (SE = 0.2208, n = 7.81) 0.49 (SE = 0.1404, n = 16.03) 
Received Treatment 0.60 (SE = 0.206, n = 6.19) 0.55 (SE = 0.1063, n = 13.97) 
Improvement -0.04 (SE = 0.2155, n = 14) 0.05 (SE = 0.1611, n = 30) 
Figure 23 T + L (Treatment) VS. Trastuzumab (Control), Validated Genomic Markers, Scenario (1) & (2) 
The hinge loss cannot differentiate subgroups based on genomic markers of this data, 
either. Participants who received the treatment always obtain higher better outcomes on average. 
Thus, treatment effects for the control recommendation is always negative, but it is always positive 
for the treatment recommendation (Table 10). Interpretation to the interaction plot is similar: 
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patients always benefit more from the treatment. Participant who are assigned the control have 
slightly higher average outcomes than the treatment group under the hinge loss, which is likely to 
be cause by noise, too (Figure 24).  
Table 10 T + L (Treatment) VS. Trastuzumab (Control), Validated Gene Models, the Hinge Loss 
Cut-off Recommended Control Recommended Treatment 
Median 
Received Control 0.58 (SE = 0.1299, n = 11.48) 0.49 (SE = 0.1485, n = 11.86) 
Received Treatment 0.64 (SE = 0.1224, n = 10.52) 0.57 (SE = 0.1242, n = 10.14) 
Improvement -0.07 (SE = 0.1754, n = 22) 0.08 (SE = 0.161, n = 22) 
0 
Received Control 0.54 (SE = 0.1444, n = 9.57) 0.47 (SE = 0.143, n = 14.1) 
Received Treatment 0.58 (SE = 0.104, n = 9.52) 0.56 (SE = 0.1442, n = 10.81) 
Improvement -0.04 (SE = 0.176, n = 19.09) 0.08 (SE = 0.1787, n = 24.91) 
Figure 24 T + L (Treatment) VS. Trastuzumab (Control), Validated Genomic Markers, Scenario (3) & (4) 
Next, we assess the gain from ITR using all covariates. Under both scenarios, receiving the 
treatment always leads to higher average outcomes. In terms of the treatment recommendation, 0 
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is more lenient than the median value of benefit scores as the cutpoint, since around 28 participants 
are assigned to the treatment under scenario (2), while only around 11 participants are assigned to 
the treatment under scenario (1). The interaction between the recommended treatment and average 
outcomes can be clearly observed in Figure 25. Although differences of average outcomes exist 
between subgroups, the lines representing the treatment is above the control line, indicating no 
improvement from following ITRs. 
Table 11 T + L (Treatment) VS. Trastuzumab (Control), Validated Overall Models, the Logistic Loss 
Cut-off Recommended Control Recommended Treatment 
Median 
Received Control 0.59 (SE = 0.1294, n = 13.72) 0.51 (SE = 0.1884, n = 5.74) 
Received Treatment 0.67 (SE = 0.1006, n = 11.79) 0.56 (SE = 0.1086, n = 5.75) 
Improvement -0.09 (SE = 0.195, n = 25.51) 0.05 (SE = 0.1784, n = 11.49) 
0 
Received Control 0.46 (SE = 0.2364, n = 5) 0.56 (SE = 0.1582, n = 14) 
Received Treatment 0.63 (SE = 0.231, n = 4.37) 0.59 (SE = 0.1358, n = 13.63) 
Improvement -0.20 (SE = 0.2266, n = 9.37) 0.03 (SE = 0.2061, n = 27.63) 
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Figure 25 T + L (Treatment) VS. Trastuzumab (Control), Validated Overall Models, Scenario (1) & (2) 
The overall model was then fitted under the hinge loss. No significant gain is observed 
either. Interpretation of the resulted table is similar to previous results. One thing worth noticing 
is that under scenario (4), both subgroup achieve positive improvement. Nonetheless, for the 
control subgroup, this improvement is only 0.001, which might be caused by noise (Table 12). 
Appearing on the interaction plot, two lines for scenario (4) are overlapped on control subgroup 
(Figure 26) and no meaningful improvement can be observed. 
Table 12 T + L (Treatment) VS. Trastuzumab (Control), Validated Overall Models, the Hinge Loss 
Cut-off Recommended Control Recommended Treatment 
Median 
Received Control 0.60 (SE = 0.1534, n = 9.93) 0.50 (SE = 0.149, n = 9.28) 
Received Treatment 0.65 (SE = 0.1621, n = 9.07) 0.54 (SE = 0.1578, n = 8.72) 
Improvement -0.05 (SE = 0.2225, n = 19) 0.04 (SE = 0.2335, n = 18) 
0 
Received Control 0.64 (SE = 0.1808, n = 4.98) 0.48 (SE = 0.1763, n = 14.1) 
Received Treatment 0.64 (SE = 0.1671, n = 5.48) 0.53 (SE = 0.1312, n = 12.44) 
Improvement 0.001 (SE = 0.2282, n = 10.46) 0.06 (SE = 0.2051, n = 26.54) 
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Figure 26 T + L (Treatment) VS. Trastuzumab (Control), Validated Overall Models, Scenario (3) & (4) 
3.2.2  Trastuzumab-containing Regimens Versus Lapatinib 
It has been proven that trastuzumab has better efficacy than lapatinib.[12,20] The comparison 
between trastuzumab-containing regimens treatment and lapatinib is thus not very clinically 
meaningful. This analysis is done to assess if there is any participants have particular 
characteristics that are more sensitive to lapatinib. No significant improvement by following ITR 
is observed in any of the models we proposed under the four scenarios. In all models, patients in 
treatment subgroup always obtain higher outcomes on average than patients in control subgroup. 
For the sake of brevity, here we only report the validated subgroup identification results when all 
covariates are included.  
Overall, individualized subgroup identification does not improve participants’ outcome 
when comparing treatment effects of trastuzumab-containing regimens (the treatment) and 
lapatinib (the control). Table 13 shows that for both cutpoints under scenario (1) and (2), 
participants always have higher outcomes on average when receiving the treatment, irrespective 
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of the treatment recommendation. More directly, in the treatment and outcome interaction plot 
(Figure 27), the blue line is above the red line in both plots, meaning that the average outcome for 
participants who received the treatment are higher than that of participants who received the 
control in both treatment recommendation subgroups.  
Table 13 Trastuzumab-containing Regimens (Treatment )VS Lapatinib (Control), 
Validated Overall Models, the Logistic Loss 
Cut-off Recommended Control Recommended Treatment 
Median 
Received Control 0.45 (SE = 0.1778, n = 10.38) 0.42 (SE = 0.157, n = 7.9) 
Received Treatment 0.49 (SE = 0.1467, n = 20.05) 0.61 (SE = 0.1131, n = 16.67) 
Improvement -0.04 (SE = 0.1721, n = 30.43) 0.19 (SE = 0.1585, n = 24.57) 
0 
Received Control 0.25 (SE = 0.3048, n = 1.31) 0.43 (SE = 0.1258, n = 16.54) 
Received Treatment 0.31 (SE = 0.2841, n = 3.64) 0.57 (SE = 0.0707, n = 33.51) 
Improvement -0.19 (SE = 0.3003, n = 4.95) 0.14 (SE = 0.1516, n = 50.05) 
Figure 27 Trastuzumab-containing Regimens (Treatment )VS Lapatinib (Control), 
Validated Overall Models, Scenario (1) & (2) 
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Results for the hinge loss are similar to what we obtain under the logistic loss. Participants 
who received the treatment have higher average outcomes in both scenarios. Hence, treatment 
effects are always positive for the treatment recommendation, but always negative for the control 
recommendation. In the interaction plots for the two scenarios (Figure 28), the blue lines that 
representing treatment received group are above the red lines that representing control received 
group in both plots, indicating no improvement from ITRs. 
 
Table 14 Trastuzumab-containing Regimens (Treatment )VS Lapatinib (Control),  
Validated Overall Models, the Hinge Loss 
Cut-off  Recommended Control Recommended Treatment 
Median Received Control 0.42 (SE = 0.1555, n = 8.47) 0.45 (SE = 0.1596, n = 9.16) 
Received Treatment 0.56 (SE = 0.1108, n = 19.53) 0.58 (SE = 0.1158, n = 17.84) 
Improvement -0.14 (SE = 0.2134, n = 28) 0.13 (SE = 0.2174, n = 27) 
0 Received Control 0.06 (SE = 0.0962, n = 0.36) 0.39 (SE = 0.1071, n = 17.64) 
Received Treatment 0.60 (SE = 0.1624, n = 1.15) 0.54 (SE = 0.0766, n = 35.85) 




Figure 28 Trastuzumab-containing Regimens (Treatment )VS Lapatinib (Control), 




With recent advance in biotechnology, large amount of biomarkers from different 
platforms become available in the past decade. Precision medicine emerges as an important issue 
that these markers could help to identify patient heterogeneity in treatment response and lead to 
better patient management and more effective treatment regimens. Individualized treatment rule 
provides a useful perspective about precision medicine and obtaining an optimal ITR from existing 
data supplies a natural application in precision medicine. Following several methods that attempt 
to define and estimate an optimal ITR, Chen et al. (2017)[8] proposed a general framework for the 
optimality of an ITR under various choices of loss functions or risk functions, and subsequent 
estimation and inference procedure. Huiling and Yu (2018)[10] incorporated this framework into 
an R package, “personalized”. We applied this package to analyze a sub-study of the NSABP B-
41 study. [Robidoux et al., 2013] It was demonstrated that both clinical markers and genomic 
markers from the PAM50 panel could lead to much improved and promising patient management 
scheme had the estimated optimal ITR been applied to the same group of patients with the amount 
of improvement in the pCR varying from 0.43 to 0.56 in various subgroups, as shown in Tables 2, 
4 and 6 where the hinge loss function was applied. However, internal validation via repeatedly 
random splitting into training data sets and testing data sets did not produce consistent 
improvement in the pCR had the estimated optimal ITRs been applied to the testing datasets. The 
ITR-based methods provide a powerful tool to identify predictive treatment markers and optimal 
scheme for marker-directed treatment assignment, and lead to precision medicine in practice. 
However, the performance of the developed ITRs need to be validated via external validation 
before their application.   
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Appendix A Example R Code 
Below is an example of the workflow of subgroup identification using the “personalized” 
package in R. The process shown here is using the clinical markers model to compare treatment 
efficacy between T + L and Trastuzumab under the logistic loss. 
 
library(personalized) 
mydata_full = read.csv("filepath", header = T, stringsAsFactors = T) 
sapply(mydata_full, class) 
factors = c(4,8,9,10,11,12,106,108:110,112,114:130,132,133:135,195:198) 
mydata_full[,factors] = lapply(mydata_full[,factors], factor) 
groups = c(1,3) 
mydata_13 = mydata_full[mydata_full$TRT %in% groups,]  #select out group 1 and group 3 
 
levels(mydata_13$TRT) 
levels(mydata_13$TRT) = c(0,NA,1)  # 0 for Trastuzumab, 1 for Trastuzumab+Lapatinib 
levels(mydata_13$RACE) 
levels(mydata_13$RACE) = c(1,0,0,0,NA)   # 1 for White, 0 for non-white 
levels(mydata_13$ER) 
levels(mydata_13$ER) = c(1,0)  # 1 for positive, 0 for negative 
levels(mydata_13$LymphNodeInv) 
levels(mydata_13$LymphNodeInv) = c(1,0)  # 1 for positive, 0 for negative 
levels(mydata_13$HER2IHC) 
levels(mydata_13$HER2IHC) = c(0,0,0,1,NA)   # 1 for strong, 0 for weak 
levels(mydata_13$Subtype_BX) 
levels(mydata_13$Subtype_BX) = c(0,1,0,0) 
mydata_13$TRT = as.numeric(as.character((mydata_13$TRT))) 
mydata_13$PCRBRNode = as.numeric(as.character((mydata_13$PCRBRNode))) 
mydata_13$RACE = as.numeric(as.character((mydata_13$RACE))) 
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mydata_13$LymphNodeInv = as.numeric(as.character((mydata_13$LymphNodeInv))) 
mydata_13$ER = as.numeric(as.character((mydata_13$ER))) 
mydata_13$HER2IHC = as.numeric(as.character((mydata_13$HER2IHC))) 




                            "pseudo_ID")] 
summary(mydata_cm131$TRT==1) 
mydata_cm13 = na.omit(mydata_cm131) 
summary(mydata_cm13$TRT==1) 
x_cm131 = data.matrix(mydata_cm13[,c(3:9)],rownames.force = NA) 
x_cm13 = x_cm131[,1:6] 
trt_cm13 = as.factor(mydata_cm13[,c(1)]) 
levels(trt_cm13) = c("Ctrl", "Trt")   # Trt: Trastuzumab+Lapatinib group; Ctrl: 
Lapatinib group 
trt_cm13 = as.character(trt_cm13) 
y_cm13 = as.numeric(mydata_cm13[,c(2)]) 
 
gene_type13 = mydata_13[c(133,137:194,200)] 
x_gn131 = data.matrix(gene_type13, rownames.force = NA) 
x_gn13 = x_gn131[,1:59]  
trt_gn13 = as.factor(mydata_13[,c(4)]) 
levels(trt_gn13) = c("Ctrl", "Trt")     
trt_gn13 = as.character(trt_gn13) 
y_gn13 = as.numeric(mydata_13$PCRBRNode) 
 
x_all131 = merge(x_cm131,x_gn131,by = "pseudo_ID") 
x_all13 = data.matrix(x_all131[,2:66]) 
 
propensity.func.13 <- function(x, trt) 82/(82+94)  
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# Find patients subgroups using clinical markers with the lasso 
 
# Since propensity score is constant, augmentation function is not necessary 
# fit.subgroup function does not work when there's missing data 
set.seed(123) 
subgrp13.cm.lasso <- fit.subgroup(x = x_cm13, y = y_cm13, trt = trt_cm13,  
                                  propensity.func = propensity.func.13, 
                                  loss = "logistic_loss_lasso", method = "weighting", 
                                  cutpoint = "median", larger.outcome.better = TRUE,  




subgrp13.cm.lasso0 <- fit.subgroup(x = x_cm13, y = y_cm13, trt = trt_cm13,  
                                   propensity.func = propensity.func.13, 
                                   loss = "logistic_loss_lasso", method = "weighting", 
                                   cutpoint = 0, larger.outcome.better = TRUE,  
                                   retcall = TRUE,nfolds = 10) 
summary(subgrp13.cm.lasso0) 
 
# Compare received and recommended treatment  
received13.trt.lasso.cm = data.frame(subgrp13.cm.lasso$trt.received) 
recommended13.trts.lasso.cm = data.frame(subgrp13.cm.lasso$recommended.trts)   
compare13.trt.lasso.cm = cbind(received13.trt.lasso.cm, recommended13.trts.lasso.cm) 
compare13.trt.lasso.cm 
 
received13.trt.lasso0.cm = data.frame(subgrp13.cm.lasso0$trt.received) 
recommended13.trts.lasso0.cm = data.frame(subgrp13.cm.lasso0$recommended.trts)   





# Summarize significant covariates 
print(summarize.subgroups(subgrp13.cm.lasso), p.value = 0.05) 
print(summarize.subgroups(subgrp13.cm.lasso0), p.value = 0.05) 
 
# Cross validation for clinical markers model using multiple replications method 
class(subgrp13.cm.lasso) 
validation13.cm.lasso <- validate.subgroup(subgrp13.cm.lasso, B = 100,  
                         method = "training_test_replication",train.fraction = 0.75) 
                         validation13.cm.lasso 
 
validation13.cm.lasso0 <- validate.subgroup(subgrp13.cm.lasso0, B = 100,  
                          method = "training_test_replication",train.fraction = 0.75) 
                          validation13.cm.lasso0 
 
# Plots of patient outcomes conditional on treatment 
plotCompare(subgrp13.cm.lasso,subgrp13.cm.lasso0,type = "boxplot") 
plotCompare(subgrp13.cm.lasso,subgrp13.cm.lasso0,type = "density") 
plotCompare(subgrp13.cm.lasso,subgrp13.cm.lasso0,type = "interaction") 
plotCompare(subgrp13.cm.lasso,subgrp13.cm.lasso0,type = "conditional") 
 
plotCompare(validation13.cm.lasso,validation13.cm.lasso0,type = "boxplot") 
plotCompare(validation13.cm.lasso,validation13.cm.lasso0,type = "density") 
plotCompare(validation13.cm.lasso,validation13.cm.lasso0,type = "interaction") 
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